arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Charles River Laboratories International, Inc.

CRL Health Care Biotechnology: Commercial Physical & Biological Resarch
$288.50
▼ -0.0% Today
as of Sep 4, 16:47 ET
Last 30 days +19.99% Jul 28 → Sep 04
$225.45 $245.09 $264.72 $284.36 $304.00 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$288.29
High
$291.64
Low
$285.34
Volume
$735,576
Avg Vol
$928,147
Mkt Cap
$13.4B
P/E (TTM)
374.68
Beta
—
52w High
$303.31
52w Low
$144.26
Div Yield
—
Shares Out
$48M

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 15:30 Zacks
Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
Sep 1 · 14:59 Zacks
Here's Why You Should Hold Charles River Stock in Your Portfolio Now
Sep 1 · 14:30 Zacks
Is This the Right Time to Add CRL Stock to Your Portfolio?
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$144
$303
91% of range
Avg surprise (last 3)
+14.5%
Avg reaction (last 2)
+9.3%
50% positive
Latest IV / EM
43%
EM ±6.7% · $290 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.03$0.76$1.54$2.33$3.12 Actual $2.01Actual $1.89Actual $1.69Actual $1.30Actual $1.74Actual $1.33Actual $2.34Est $2.06Actual $3.12Est $2.50Actual $1.10Actual $2.06Est $1.96Actual $-0.03 AprJulSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-15M$260M$534M$809M$1.1B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Sat Jun 27, 2026Jun 2026 $-0.03 — — — — financials
Thu May 7, 2026Mar/2026 $2.06 $1.96 +5.1% -12.0% -0.0% earnings
Sat Sep 27, 2025Sep 2025 $1.10 — — — — financials
Wed Aug 6, 2025Jun/2025 $3.12 $2.50 +24.8% — — earnings
Wed May 7, 2025Mar/2025 $2.34 $2.06 +13.6% — +18.7% earnings
Sat Sep 28, 2024Sep 2024 $1.33 — — — — financials
Sat Jun 29, 2024Jun 2024 $1.74 — — — — financials
Sat Mar 30, 2024Mar 2024 $1.30 — — — — financials
Sat Sep 30, 2023Sep 2023 $1.69 — — — — financials
Sat Jul 1, 2023Jul 2023 $1.89 — — — — financials
Sat Apr 1, 2023Apr 2023 $2.01 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$1.00B$996M—$1.00B$1.03B$984M—$1.01B
Cost of revenue———————$661M
Gross profit————————
Operating income$120M$120M—$134M$100M$75M—$117M
Net income$-1M$-15M—$54M$52M$25M—$70M
EPS (diluted)$-0.03$-0.30—$1.10$1.06$0.50—$1.33

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$192M$192M$214M$207M$183M$229M$195M$210M
Inventory$346M$360M$299M$303M$280M$290M$279M$336M
Total current assets$1.53B$1.49B$1.45B$1.53B$1.47B$1.51B$1.40B$1.49B
Total assets$7.53B$7.73B$7.14B$7.51B$7.56B$7.58B$7.53B$8.00B
Long-term debt————————
Total liabilities$4.64B$4.74B$3.92B$4.06B$4.16B$4.34B$4.02B$4.18B
Total equity$2.84B$2.95B$3.16B$3.41B$3.36B$3.20B$3.46B$3.79B

Implied volatility — last 90 days

40%48%57%65%73% Jun 07 — IV 60% · EM ±8.2%Jun 08 — IV 60% · EM ±7.9%Jun 09 — IV 56% · EM ±7.0%Jun 10 — IV 56% · EM ±6.6%Jun 11 — IV 58% · EM ±6.4%Jun 12 — IV 56% · EM ±5.7%Jun 15 — IV 61% · EM ±4.4%Jun 16 — IV 62% · EM ±3.7%Jun 17 — IV 74% · EM ±3.1%Jun 19 — IV 50% · EM ±11.0%Jun 22 — IV 52% · EM ±10.8%Jun 23 — IV 49% · EM ±10.0%Jun 24 — IV 51% · EM ±10.2%Jun 25 — IV 51% · EM ±9.9%Jun 26 — IV 46% · EM ±8.9%Jun 29 — IV 49% · EM ±8.7%Jun 30 — IV 48% · EM ±8.2%Jul 01 — IV 45% · EM ±7.6%Jul 02 — IV 44% · EM ±7.2%Jul 03 — IV 46% · EM ±7.2%Jul 06 — IV 48% · EM ±6.7%Jul 07 — IV 50% · EM ±6.6%Jul 08 — IV 52% · EM ±6.5%Jul 09 — IV 48% · EM ±5.6%Jul 10 — IV 49% · EM ±5.4%Jul 13 — IV 58% · EM ±4.8%Jul 14 — IV 57% · EM ±4.1%Jul 15 — IV 51% · EM ±3.0%Jul 16 — IV 58% · EM ±2.4%Jul 20 — IV 60% · EM ±14.2%Jul 21 — IV 62% · EM ±14.3%Jul 22 — IV 61% · EM ±14.0%Jul 23 — IV 62% · EM ±14.0%Jul 24 — IV 64% · EM ±14.1%Jul 27 — IV 66% · EM ±13.7%Jul 28 — IV 66% · EM ±13.4%Jul 29 — IV 66% · EM ±13.2%Jul 30 — IV 64% · EM ±12.6%Jul 31 — IV 66% · EM ±12.6%Aug 03 — IV 73% · EM ±12.9%Aug 04 — IV 74% · EM ±12.7%Aug 05 — IV 53% · EM ±8.9%Aug 06 — IV 49% · EM ±7.9%Aug 07 — IV 46% · EM ±7.3%Aug 10 — IV 46% · EM ±6.4%Aug 11 — IV 48% · EM ±6.3%Aug 12 — IV 47% · EM ±5.9%Aug 13 — IV 46% · EM ±5.5%Aug 14 — IV 43% · EM ±4.7%Aug 17 — IV 50% · EM ±4.2%Aug 18 — IV 48% · EM ±3.5%Aug 19 — IV 53% · EM ±3.1%Aug 20 — IV 64% · EM ±2.7%Aug 24 — IV 44% · EM ±9.2%Aug 25 — IV 40% · EM ±8.3%Aug 26 — IV 42% · EM ±8.4%Aug 27 — IV 43% · EM ±8.3%Aug 28 — IV 42% · EM ±8.0%Aug 31 — IV 41% · EM ±7.3%Sep 01 — IV 45% · EM ±7.7%Sep 02 — IV 44% · EM ±7.3%Sep 03 — IV 42% · EM ±6.8%Sep 04 — IV 43% · EM ±6.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in